Marcel Levi Selected Research

Marcel Levi Research Topics

Disease

72	Sepsis (Septicemia) 02/2024 - 01/2002
57	Inflammation (Inflammations) 01/2024 - 05/2002
51	Disseminated Intravascular Coagulation 11/2023 - 01/2002
51	Hemorrhage 11/2023 - 11/2002
34	Thrombosis (Thrombus) 10/2023 - 01/2002
31	Infections 02/2024 - 04/2002
23	Pneumonia (Pneumonitis) 01/2021 - 04/2002
18	COVID-19 02/2024 - 01/2020
15	Wounds and Injuries (Trauma) 10/2023 - 04/2005
14	Neoplasms (Cancer) 06/2021 - 03/2002
13	Thrombocytopenia (Thrombopenia) 10/2022 - 03/2002
12	Critical Illness (Critically Ill) 01/2021 - 01/2006
11	Pneumococcal Pneumonia 03/2015 - 04/2002
11	Acute Lung Injury 01/2013 - 05/2003
10	Endotoxemia 09/2012 - 10/2002
9	Hereditary Angioedemas 01/2023 - 10/2005
9	Venous Thromboembolism 06/2021 - 03/2002
9	Lung Injury 11/2017 - 10/2006
7	Angioedema 11/2022 - 04/2006
7	Thrombotic Microangiopathies 07/2020 - 11/2003
7	Ischemia 01/2017 - 03/2002
7	Acute Coronary Syndrome 12/2011 - 02/2002
6	Venous Thrombosis (Deep-Vein Thrombosis) 10/2022 - 01/2002
6	Atrial Fibrillation 09/2011 - 02/2004
5	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 06/2021 - 07/2008
5	Delirium 10/2014 - 05/2007
5	Stroke (Strokes) 09/2009 - 02/2004
4	Shock 03/2023 - 05/2008
4	Thromboembolism 01/2020 - 02/2004
4	Human Influenza (Influenza) 10/2011 - 11/2006
4	Hyperglycemia 07/2008 - 02/2006
4	Peritonitis 05/2007 - 06/2004
3	Communicable Diseases (Infectious Diseases) 02/2024 - 04/2013
3	Multiple Organ Failure (MODS) 11/2023 - 02/2005
3	Disease Progression 01/2023 - 06/2019
3	Intracranial Sinus Thrombosis (Sinus Thrombosis) 01/2022 - 01/2021
3	Hemophilia A (Haemophilia) 07/2020 - 04/2005
3	Acquired angioedema 01/2019 - 04/2006
3	Cardiovascular Diseases (Cardiovascular Disease) 06/2014 - 05/2008
3	Melioidosis 01/2013 - 03/2010

Drug/Important Bio-Agent (IBA)

53	AnticoagulantsIBA 01/2022 - 11/2002
45	Dacarbazine (DIC)FDA LinkGeneric 11/2023 - 01/2002
33	Protein CIBA 11/2017 - 06/2003
32	FibrinIBA 06/2021 - 12/2002
30	Thrombin FDA Link 10/2023 - 03/2002
26	AntithrombinsIBA 08/2023 - 06/2004
23	Thromboplastin (Tissue Factor)IBA 10/2023 - 02/2002
21	Hemostatics (Antihemorrhagics)IBA 02/2024 - 05/2002
20	Heparin (Liquaemin)FDA LinkGeneric 08/2023 - 01/2002
18	CytokinesIBA 01/2024 - 05/2002
15	Blood Coagulation Factors (Coagulation Factor)IBA 11/2022 - 08/2003
12	Proteins (Proteins, Gene)FDA Link 06/2019 - 04/2003
9	fibrin fragment D (D-dimer)IBA 02/2022 - 04/2003
8	Interleukin-6 (Interleukin 6)IBA 02/2022 - 03/2004
8	Factor VIIa (Activated Factor VII)IBA 11/2010 - 01/2003
7	ThrombomodulinIBA 08/2023 - 07/2010
7	Plasminogen InactivatorsIBA 03/2015 - 08/2003
7	recombinant FVIIa (rFVIIa)FDA Link 11/2010 - 11/2002
6	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2005
6	Fibrinolysin FDA Link 10/2019 - 03/2004
6	Fibrin Fibrinogen Degradation ProductsIBA 10/2011 - 04/2003
6	drotrecogin alfa activated (Xigris)FDA Link 01/2011 - 10/2005
5	ChemokinesIBA 01/2024 - 10/2005
5	PlasminogenIBA 10/2019 - 08/2003
5	danaparoid (Orgaran)FDA Link 11/2017 - 01/2009
5	Plasminogen Activators (Plasminogen Activator)IBA 10/2012 - 04/2002
5	Prothrombin (Factor II)IBA 05/2011 - 10/2005
4	Proteinase-Activated ReceptorsIBA 10/2023 - 03/2008
4	ChAdOx1 nCoV-19IBA 01/2022 - 01/2021
4	von Willebrand FactorIBA 07/2020 - 04/2008
4	antithrombin III-protease complexIBA 01/2020 - 04/2003
4	Fibrinogen (Factor I)FDA Link 01/2020 - 04/2003
4	lipoprotein-associated coagulation inhibitor (TFPI)IBA 11/2017 - 08/2002
4	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2016 - 03/2002
4	Peptide Hydrolases (Proteases)FDA Link 01/2016 - 01/2004
4	LipopolysaccharidesIBA 01/2013 - 09/2008
4	CoagulantsIBA 08/2012 - 05/2006
4	Plasminogen Activator Inhibitor 1IBA 07/2012 - 08/2003
4	Antifibrinolytic Agents (Antifibrinolytics)IBA 06/2012 - 01/2006
4	Vitamin K FDA Link 10/2010 - 05/2008
4	EndotoxinsIBA 07/2008 - 06/2003
3	Oxygen (Dioxygen)IBA 02/2024 - 11/2006
3	VaccinesIBA 10/2022 - 10/2021
3	tocilizumab (atlizumab)FDA Link 01/2022 - 01/2020
3	Messenger RNA (mRNA)IBA 01/2022 - 08/2003
3	Complement System Proteins (Complement)IBA 10/2019 - 10/2007
3	Peptides (Polypeptides)IBA 11/2017 - 10/2002
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2017 - 01/2010
3	Factor Xa InhibitorsIBA 08/2016 - 11/2002
3	Enoxaparin (Lovenox)FDA LinkGeneric 03/2016 - 08/2003
3	Endothelial Protein C ReceptorIBA 05/2014 - 09/2012
3	factor V LeidenIBA 07/2013 - 01/2010
3	Interleukin-8 (Interleukin 8)IBA 10/2012 - 05/2007
3	Tissue Plasminogen Activator (Alteplase)FDA Link 07/2012 - 01/2006
3	Saline SolutionIBA 10/2011 - 06/2004

Therapy/Procedure

27	Therapeutics 11/2022 - 03/2002
5	Drug Therapy (Chemotherapy) 06/2021 - 03/2002
5	Artificial Respiration (Mechanical Ventilation) 12/2012 - 09/2005
4	Critical Care (Surgical Intensive Care) 01/2020 - 09/2005
3	Stents 12/2011 - 01/2009